SYRS Syros Pharmaceuticals Inc.: Earnings per one share for the last 12 months

Syros Pharmaceuticals (SYRS) is integrating bioethics and environmental control principles into the development of genetic medicines. However, capital shortages and the risks of clinical trial failures pose serious threats. The year-over-year EPS growth dynamics over a rolling period visualize this balance, where the current parameter equals 76.70. Business stability is maintained by outsourcing research to external CROs under strict management supervision.
SYRS (syros.com): analytical breakdowns and indicator data

Syros Pharmaceuticals (SYRS) operates in the high-risk zone of clinical trials, where confidence in technology drives capitalization. This relative EPS YoY TTM growth metric smooths out quarterly volatility by calculating the percentage change in earnings per share over a rolling year. Analyzing the line's trajectory allows for the identification of a systemic decline in profitability before a market crash occurs. For the cautious biotech sector, such price action serves as an indicator of operational resilience. Monitoring this metric helps distinguish temporary development challenges from fundamental business degradation.